Changes of serum levels of MIP-1β in inactive hepatitis B surface antigen carriers treated with pegylated-interferon
CAO Zhen-huan
LIU Ya-li
MA Li-na
ZHENG Yan-hong
WANG Qun
WANG Jun-li
WU Fang-fang
CHEN Xin-yue
Abstract：Objective To investigate the correlation of HBsAg clearance with serum MIP-1β level in inactive hepatitis B surface antigen carrier (IHC) treated with pegylated-interferon (Peg-IFN). Methods Twenty IHCs were enrolled in this study after 24 weeks of Peg-IFN treatment, including 13 patients achieving HBsAg clearance (R group) and 7 patients not achieving HBsAg clearance (NR group). Serum MIP-1β levels in IHCs were detected by Luminex technology at baseline after 12 weeks and 24 weeks of treatment. In addition, serum MIP-1β levels in 11 healthy controls (HC group) were detected. The correlation of serum MIP-1β with HBsAg clearance was investigated by comparing the baseline serum MIP-1β level and post-treatment trends of R and NR groups. Results There were no statistical significant differences of serum MIP-1β level between R, NR and HC groups (F=0.320, P=0.729). After Peg-IFN treatment, serum MIP-1β level decreased significantly in R group, comparing to baseline data (F=4.532, P=0.018). Serum MIP-1β level showed a horizontal fluctuation and no significantly change in NR group, comparing to baseline data (F=0.071, P=0.932). Conclusions After Peg-IFN treatment, serum MIP-1β level in IHC obviously decreases. This treatment may benefit HBsAg clearance.
Keywords：inactive HBsAg carrierspegylated-interferonHBsAg clearanceMIP-1β
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 436-438,457 )